Citations

Clear

1422 citation(s) found for "White, JB".

Predictors of adverse events and early mortality after esophageal stent placement in a low resource setting: a series of 3823 patients in Kenya
Parker, Robert K. , Lando, Justus , Simel, Ian , Chol, Nyail, Ranketi, Sinkeet, Chepkwony, Robert, Pyego, Linus, Chepkirui, Caren, Chepkemoi, Winnie, Fleischer, David E., Topazian, Mark , Burgert, Steve, White, Russell E., Fleischer, David, Mwachiro, Michael , Dawsey, Sanford M. , Burgert, Stephen L.

Mayo Clinic

Endoscopy International Open | April 14, 2022 | Volume: 10 | Issue: 04 | Pages: E479-E487

10.1055/a-1783-9829 | PMID 35433219 Get It

Abstract Background and study aims Dysphagia from esophageal cancer may be palliated with self-expanding metallic stents (SEMS). Controversy exists about the use of dilation before SEMS deployment. Patients and methods We performed a retrospective cohort study of patients who had SEMS placement without fluoroscopy for palliation at Tenwek Hospital in Bomet, Kenya between January 1999 and April 2019. The primary outcome was any serious adverse event (AE) (chest pain, stent migration, perforation, bleeding, or all-cause mortality) within 30 days of the procedure. Various demographic and clinical characteristics, and procedural details, were examined as risk factors. Technical success, defined as correct SEMS placement, and clinical success, defined as dysphagia score improvement without 30-day mortality, were examined. Results A total of 3823 patients underwent SEMS placement, with 2844 (74.4 %) placed in the second decade of the study. Technical and clinical success were achieved in 97.2 % and 95.5 %, respectively, with mean dysphagia scores improving from 3.4 (SD 0.6) to 0.9 (SD 1.3) post-stent placement. AEs occurred in 169 patients (4.4 %). AEs, specifically perforations, were associated with dilation to greater than 36F in the first decade. Perforation rates decreased from the first (4.1 %) to the second decade (0.2 %). Only 30% had complete 30-day follow-up data. Conclusions SEMS placement is a safe, effective method of palliating malignant dysphagia, with low rates of AEs and 30-day mortality and high rates of clinical and technical success. Dilation can facilitate placement of SEMS without fluoroscopy but should not be performed above 36F due to the risk of perforation.
Colonoscopy Findings in FIT+ and mt-sDNA+ Patients versus in Colonoscopy-only Patients: New Hampshire Colonoscopy Registry Data
Anderson, Joseph C. , Robinson, Christina M. , Hisey, William , Butterly, Lynn F. , Limburg, Paul J.

Mayo Clinic

Cancer Prevention Research | April 4, 2022 | Volume: 15 | Issue: 7 | Pages: 455-464

10.1158/1940-6207.capr-21-0581 | PMID 35378546 Get It

Abstract Few studies compare fecal immunochemical test (FIT) and multi-target stool DNA (mt-sDNA) outcomes in practice. We compared colonoscopy yield following FIT+ or mt-sDNA+ tests to colonoscopies without preceding stool tests in the comprehensive population-based New Hampshire Colonoscopy Registry (NHCR). Outcomes were any neoplasia and an ordered outcome: adenocarcinoma, advanced neoplasia (adenoma/serrated polyp ≥ 1 cm/villous/high-grade dysplasia), nonadvanced neoplasia, or normal. Our total sample included 306 mt-sDNA+ (average age ± SD 67.0 ± 7.9), 276 FIT+ (66.6 ± 8.7), and 50,990 colonoscopy-only patients (61.8 ± 8.1). Among average-risk patients (N = 240 mt-sDNA+, N = 194 FIT+, N = 26,221 colonoscopy only), mt-sDNA+ patients had a higher risk for any neoplasia (67.1%) compared with FIT+ (54.6%, P = 0.00098) or colonoscopy (40.8%, P < 0.0001). Severity of findings and histology subtypes differed across the three groups (P < 0.0001 for both), with a higher yield of advanced findings in mt-sDNA+ patients. In particular, clinically relevant serrated polyps (hyperplastic polyps ≥10 mm/traditional serrated adenomas/sessile serrated polyps) were detected at a higher frequency in mt-sDNA+ patients as compared with FIT+ or colonoscopy-only patients. Even after adjustment, patients with positive mt-sDNA [OR = 2.82; 95% confidence interval (CI), 2.00–4.02] or FIT+ tests (OR = 1.67; 95% CI, 1.19–2.36) were more likely to have histologically more advanced findings than colonoscopy alone. At follow-up colonoscopy, mt-sDNA+ tests were more likely to predict neoplasia than FIT+, largely due to increased detection of serrated polyps. Prevention Relevance: Colorectal cancer screening options include colonoscopy and stool-based tests, including the fecal immunochemical test (FIT) and the multi-target stool DNA (mt-sDNA) test which, if positive, must be followed by a colonoscopy. Assessing “real-world” outcomes of colonoscopies following positive stool tests can inform their clinical use. See related Spotlight, p. 417
Abstract 1: Did Carotid Stenting and Endarterectomy Outcomes Change Over Time in the Carotid Revascularization Endarterectomy versus Stenting Trial?
Roubin, Gary S., Hopkins, L. Nelson , Moore, Wesley S. , Gray, William A. , Katzen, Barry T. , Chakhtoura, Elie, Morrish, William, Ferguson, R. , Shawl, Fayaz A., Harrigan, Mark R. , Voeks, Jenifer H. , Lal, Brajesh K. , Brott, Thomas G. , Howard, George , Rosenfield, Kenneth , Hye, Robert J. , Meschia, James F.

Mayo Clinic

Stroke | March 20, 2022 | Volume: 43 | Issue: suppl_1 | Pages: No page available

10.1161/str.43.suppl_1.a1 Get It

Background The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) enrolled 2502 patients between December of 2000 and mid-July of 2008. We analyzed temporal changes in outcomes for both CEA and CAS over the course of this study. Methods Enrollment was divided into 3 consecutive epochs (5 years, 14 months, and 16 months), each with approximately 834 patients ( Table ). Rates for the primary outcome of death, stroke, and myocardial infarction (DSMI) and for death and stroke (DS) during the periprocedural period were calculated. Poisson regression was used to adjust rates for age, sex, dyslipidemia, and symptomatic status, all of which were found to influence outcomes. Results For CAS, there was a 26% decline in DSMI (6.2% → 4.6%) and a 35% decline in DS (5.5% → 3.6%). For both composite endpoints in CEA there was no consistent pattern ( Table ). As CREST progressed, it enrolled younger patients, more men, patients more likely to be dyslipidemic and enrolled more asymptomatic patients (all p < 0.05). Adjustment for these changes mediated the improvement in event rates for the CAS patients, and had no consistent effect on CEA event rates ( Table ). Conclusion Periprocedural safety for CAS improved over time in CREST. Changes were inconsistent for CEA. Improvements for CAS in part appear to reflect changes in patient selection related to age, sex, and risk factors, as adjustment for those variables attenuated the decline in rates. Linking rates to operator experience was not feasible because of the large number of new interventionalists and surgeons entering CREST over time.
Abstract 215: Validation of a Simple White-light 3D Body Volume Scanner to Assess Body Composition
Jenkins, Sarah M. , Zundel, Jennifer, Johnson, Lynne L. , Jean, Nathalie, Medina‐Inojosa, José R. , Somers, Virend K. , Johnson, Lynne, López-Jiménez, Francisco

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 8 | Issue: suppl_2 | Pages: No page available

10.1161/circoutcomes.8.suppl_2.215 Get It

Introduction: Estimating body fat content has shown to better predict adiposity-related cardiovascular risk than the commonly used body mass index (BMI). The white-light 3D Body Volume Index Scanner (BVI) is a non-invasive device normally used in the clothing industry to asses body shapes and sizes. We assessed the hypothesis that volume obtained by BVI is comparable to the volume obtained by air displacement plethysmography (BodPod) (COSMED Concord, CA, USA) and thus capable of assessing body fat mass using the bicompartmental principles of body composition. Methods: We compared BVI to BodPod, a validated bicompartmental method to assess body fat percent that uses pressure/volume relationships in isothermal conditions to estimate body volume. Volume is then used to calculate body density (BD) applying the formula density= Body mass/Volume. Body fat mass percentage is then calculated using the Siri formula (4.95/BD – 4.50) х 100. Subjects were members of the Mayo Clinic Dan Abraham Healthy Living Center undergoing a wellness evaluation. Measurements from both devices were obtained the same day. A prediction model for total BodPod volume was developed using linear regression based on 80% of the observations (N=971), as follows: Predicted BodPod Volume (L) = 9.498 + 0.805*(BVI volume, L) - 0.0411*(Age, years) - 3.295*(Male=0, Female=1) + 0.0554*(BVI volume, L)*(Male=0, Female=1) + 0.0282*(Age, years)*(Male=0, Female=1). Predictions for BodPod volume based on the estimated model were then calculated for the remaining 20% (N=243) and compared to the volume measured by the BodPod. Results: Mean (SEM) age was 41.5(0.41) years, 39.4% were men, weight 81.6(0.67) kg, BMI was 27.8 (0.20) kg/m2. Average difference between volume measured by BodPod- predicted volume by BVI was 0.0 L, median: -0.4 L, IQR: -1.8 L to 1.5 L. Average difference between Body fat % measured - predicted was -1%, median: -2.7%, IQR: -13.2 to 9.9, R2 = 0.9845 (Figure 1-A, B). Conclusion: Body fat mass can be estimated using volume measurements obtained by a white- light 3D body scanner (Figure 1-A).
Abstract 17006: Is White Rice Consumption a Risk for Cardiovascular Disease? A Systematic Review and Meta-analysis
Krittanawong, Chayakrit , Tunhasiriwet, Anusith, Bisanz, Kimberly J , Zhang, Hongju, Marysia, Tweet S, Krittanawong, Chayakrit , Prokop, Larry J. , Chirapongsathorn, Sakkarin , Wang, Zhen , Hayes, Sharonne N.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.17006 Get It

Introduction: Current proposed Dietary Guidelines for Americans, 2015 suggested replacing refined grains (e.g., white rice) with whole grains (e.g., brown rice) for improved health outcomes; however, the association between white rice consumption and risk of cardiovascular disease (CVD) was not fully investigated. The purpose of this study was to explore the associations between rice consumption, metabolic syndrome and cardiovascular disease. Methods: We conducted a comprehensive search of MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Scopus, and the Cochrane Central Register of Controlled Trials from database inception through May 2015. Observational studies were included if the studies reported hazard ratios (HRs) or odd ratios (ORs) of the associations between rice consumption, metabolic syndrome and cardiovascular disease. Data were extracted by one reviewer and then reviewed by two independent reviewers. Conflicts were resolved through consensus. Using the DerSimonian and Laird random effects models, we calculated pooled HRs and pooled ORs with 95% confidence intervals (95% CIs). Subgroup analyses were performed to explore potential sources of heterogeneity. The quality of the included studies and publication bias were assessed. Results: Out of 343 retrieved articles, we identified 6 cross-sectional and 9 prospective studies with a total of 575,852 individuals with 24,649 total CVD events and 4,409 metabolic syndrome cases. The highest category of white rice consumption (≥5 times/week) was associated with a 37% higher risk of metabolic syndrome (pooled OR, 1.37; 95% CI: 1.03-1.84; p<0.001; I 2 = 78.7%) but not a higher risk of cardiovascular disease (pooled HR, 1.01; 95% CI: 0.95-1.08; p=0.65; I 2 = 0%), compared to the lowest category (≤1 time/month). Conclusions: Higher white rice consumption has not been shown to increase the risk of cardiovascular diseases but may be associated with increased risk of metabolic syndrome.
Characteristics of Post-ICU and Post-COVID Recovery Clinics in 29 U.S. Health Systems
Danesh, Valerie, Boehm, Leanne M., Eaton, Tammy L., Arroliga, Alejandro C., Mayer, Kirby P., Kesler, Shelli R., Bakhru, Rita N., Baram, Michael, Bellinghausen, Amy L., Biehl, Michelle, Dangayach, Neha S., Goldstein, Nir M., Hoehn, K. Sarah, Islam, Marjan, Jagpal, Sugeet, Johnson, Annie B., Jolley, Sarah E., Kloos, Janet A., Mahoney, Eric J., Maley, Jason H., Martin, Sara F., McSparron, Jakob I., Mery, Marissa, Saft, Howard, Santhosh, Lekshmi, Schwab, Kristin, Villalba, Dario, Sevin, Carla M., Montgomery, Ashley A., Boehm, Leanne M. , Eaton, Tammy L. , Santhosh, Lekshmi , Danesh, Valerie , Mayer, Kirby P. , Arroliga, Alejandro C., Mayer, Kirby P., Kesler, Shelli R., Bakhru, Rita N., Baram, Michael, Bellinghausen, Amy L., Biehl, Michelle, Dangayach, Neha S., Goldstein, Nir M., Hoehn, K. Sarah, Islam, Marjan, Jagpal, Sugeet, Johnson, Annie B., Jolley, Sarah E., Kloos, Janet A., Mahoney, Eric J., Maley, Jason H., Martin, Sara F., McSparron, Jakob I., Mery, Marissa , Saft, Howard, Schwab, Kristin, Villalba, Darío Salvador , Sevin, Carla M., Montgomery, Ashley A.

Mayo Clinic

Critical Care Explorations | March 9, 2022 | Volume: 4 | Issue: 3 | Pages: e0658

10.1097/cce.0000000000000658 | PMID 35291316 Get It

OBJECTIVES: The multifaceted long-term impairments resulting from critical illness and COVID-19 require interdisciplinary management approaches in the recovery phase of illness. Operational insights into the structure and process of recovery clinics (RCs) from heterogeneous health systems are needed. This study describes the structure and process characteristics of existing and newly implemented ICU-RCs and COVID-RCs in a subset of large health systems in the United States. DESIGN: Cross-sectional survey. SETTING: Thirty-nine RCs, representing a combined 156 hospitals within 29 health systems participated. PATIENTS: None. INTERVENTIONS: None. MEASUREMENT AND MAIN RESULTS: RC demographics, referral criteria, and operating characteristics were collected, including measures used to assess physical, psychologic, and cognitive recoveries. Thirty-nine RC surveys were completed (94% response rate). ICU-RC teams included physicians, pharmacists, social workers, physical therapists, and advanced practice providers. Funding sources for ICU-RCs included clinical billing (n = 20, 77%), volunteer staff support (n = 15, 58%), institutional staff/space support (n = 13, 46%), and grant or foundation funding (n = 3, 12%). Forty-six percent of RCs report patient visit durations of 1 hour or longer. ICU-RC teams reported use of validated scales to assess psychologic recovery (93%), physical recovery (89%), and cognitive recovery (86%) more often in standard visits compared with COVID-RC teams (psychologic, 54%; physical, 69%; and cognitive, 46%). CONCLUSIONS: Operating structures of RCs vary, though almost all describe modest capacity and reliance on volunteerism and discretionary institutional support. ICU- and COVID-RCs in the United States employ varied funding sources and endorse different assessment measures during visits to guide care coordination. Common features include integration of ICU clinicians, interdisciplinary approach, and focus on severe critical illness. The heterogeneity in RC structures and processes contributes to future research on the optimal structure and process to achieve the best postintensive care syndrome and postacute sequelae of COVID outcomes.
Abstract P3-18-04: Evaluating de-escalation of breast radiation (DEBRA) following lumpectomy for breast conservative treatment of stage 1, hr+, HER2-, RS ≤18 breast cancer: NRG-BR007 a phase III trial
White, Julia , Harris, Eleanor ER, Mamounas, Eleftherios P. , Théberge, Valérie, Zellars, Rich C, Shumway, Dean A. , Chen, Guang‐Pei , Julian, Thomas B. , Anderson, Stewart , Harris, Eleanor E R , Mamounas, Eleftherios P. , Stover, Daniel G. , Ganz, Patricia A. , Jagsi, Reshma , Cecchini, Reena S. , Bergom, Carmen , El-Tamer, Mahmoud Bahij , Zellars, Richard C. , Wolmark, Norman

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: P3-18-04-P3-18-04

10.1158/1538-7445.sabcs21-p3-18-04 Get It

Abstract Roughly 50% of newly diagnosed breast cancer is stage 1, the majority being ER/PR positive, HER2- negative. Genomic assays such as Oncotype DX® have identified patients with reduced distant metastasis and lack of chemotherapy benefit, allowing patients to avoid excess toxicity. These genomic assays have been shown to be prognostic for local-regional recurrence (LRR). The de-escalation of therapy is of interest to patients, providers, and payers. Low risk, as identified by both the use of Oncotype and Mammaprint® is associated with low LRR after lumpectomy and breast radiotherapy. TRIAL DESIGN: In the DEBRA trial, we hypothesized that breast-conserving surgery (BCS) alone is non-inferior to BCS plus radiotherapy for in-breast cancer control and breast preservation in women intending appropriate endocrine therapy for stage 1 (ER and/or PR-positive, HER2-negative, and Oncotype DX Recurrence Score [RS] low) breast cancer. Stratification is by age (&lt;60; ≥60), tumor size (≤1 cm; &gt;1-2 cm), and RS &lt;11, RS 11-18. Patients are randomized to either breast radiotherapy (RT) plus endocrine therapy (arm 1) or to observation and endocrine therapy (arm 2). Arm 1 therapy is post-lumpectomy breast RT using standard methods (hypo- or conventional-fractionated whole breast irradiation with or without boost, accelerated partial breast irradiation) and at least 5 years of endocrine therapy (tamoxifen or aromatase inhibitor). In arm 2, at least 5 years of endocrine therapy (tamoxifen or aromatase inhibitor) will be given. The specific regimen of endocrine therapy in both arms is at the treating physician’s discretion. ELIGIBLITY: Patients who are stage 1: pT1 (2 cm), pN0, age ≥50 to &lt;70 years, status post (s/p) lumpectomy with negative margins (no ink on tumor ), s/p axillary nodal staging (SNB or AND), ER and/or PR positive by ASCO/CAP, HER2-negative by ASCO/CAP, and Oncotype DX RS of ≤18 on diagnostic core biopsy or resected specimen. ENDPOINTS: Primary: In-breast recurrence (IBR). Secondary: Breast conservation rate, invasive in-breast recurrence (IIBR), relapse free interval (RFI), distant disease-free survival (DDFS), overall survival (OS), patient-reported breast pain, patient-reported worry about recurrence, and adherence to endocrine therapy. STATISTICS: We assume a clinically acceptable difference in IBR of 4% at 10 years to judge omission of RT as non-inferior (10-year event-free survival for RT group is 95.6% versus 91.6% for the omission of RT group). To be able to detect non-inferiority with 80% power and a one sided α=0.025, and assuming that there would be a ramp-up in accrual in the first two years of the study (leveling off in Years 3-5), 1,670 (835 per arm) patients are required to be randomized. This conservatively assumes loss to follow-up will be 1% per year. Some of the T1a patients accrued to this study will have oncotype DX scores &gt;18, making them ineligible for the study. An extra step in the accrual process will require us to register 1,714 patients to ensure our final randomized cohort is 1,670 patients. Accrual: Screen 1,714 to randomize 1,670 into the study. Contact information: Protocol: CTSU member website: https://www.ctsu.org. NRG Oncology Pgh Clinical Coordinating Dpt: 1-800-477-7227 or ccd@nsabp.org. Support: U10CA180868, U10CA180822. NCT04852887. Citation Format: Julia White, Stewart J Anderson, Eleanor ER Harris, Eleftherios P Mamounas, Daniel G Stover, Patricia A Ganz, Reshma Jagsi, Reena S Cecchini, Carmen Bergom, Valerie Theberge, Mahmoud El-Tamer, Rich C Zellars, Dean A Shumway, Guang-Pei Chen, Thomas B Julian, Norman Wolmark. Evaluating de-escalation of breast radiation (DEBRA) following lumpectomy for breast conservative treatment of stage 1, hr+, HER2-, RS ≤18 breast cancer: NRG-BR007 a phase III trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-18-04.
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat
Rahaghi, Franck , Balasubramanian, Vijay , Chakinala, Murali M. , Eggert, Michael, Elwing, Jean , Feldman, Jeremy, King, Christopher S. , Klinger, James R. , Mathai, Stephen C. , McConnell, John W., Palevsky, Harold I. , Restrepo‐Jaramillo, Ricardo, Safdar, Zeenat , Sager, Jeffrey S., Sood, Namita , Sulica, Roxana, Hill, Nicholas S. , Elwing, Jean M , Mathai, Stephen C , Bourge, Robert C. , Burger, Charles D. , White, R. James

Mayo Clinic

Pulmonary Circulation | March 5, 2022 | Volume: 12 | Issue: 2 | Pages: No page available

10.1002/pul2.12055 | PMID 35514769 Get It

AbstractDual combination therapy with a phosphodiesterase‐5 inhibitor (PDE5i) and endothelin receptor antagonist is recommended for most patients with intermediate‐risk pulmonary arterial hypertension (PAH). The RESPITE and REPLACE studies suggest that switching from a PDE5i to a soluble guanylate cyclase (sGC) activator may provide clinical improvement in this situation. The optimal approach to escalation or transition of therapy in this or other scenarios is not well defined. We developed an expert consensus statement on the transition to sGC and other treatment escalations and transitions in PAH using a modified Delphi process. The Delphi process used a panel of 20 physicians with expertise in PAH. Panelists answered three questionnaires on the management of treatment escalations and transitions in PAH. The initial questionnaire included open‐ended questions. Later questionnaires consolidated the responses into statements that panelists rated on a Likert scale from −5 (strongly disagree) to +5 (strongly agree) to determine consensus. The Delphi process produced several consensus recommendations. Escalation should be considered for patients who are at high risk or not achieving treatment goals, by adding an agent from a new class, switching from oral to parenteral prostacyclins, or increasing the dose. Switching to a new class or within a class should be considered if tolerability or other considerations unrelated to efficacy are affecting adherence. Switching from a PDE5i to an SGC activator may benefit patients with intermediate risk who are not improving on their present therapy. These consensus‐based recommendations may be helpful to clinicians and beneficial for patients when evidence‐based guidance is unavailable.
The Posterior Ligament of the Incus (“White Dot”): A Reliable Surgical Landmark for the Facial Recess
McMillan, Ryan A. , Nassiri, Ashley M. , Leonel, Luciano, Rezende, Natalia , Celda, María Peris, Sweeney, Alex D. , Carlson, Matthew L.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 4, 2022 | Volume: 83 | Issue: S 01 | Pages: S1-S270

10.1055/s-0042-1743857 Get It

Targeted Regional Optimization in Action: Dose-dependent End-organ Ischemic Injury with Partial Aortic Occlusion in the Setting of Ongoing Liver Hemorrhage
Ronaldi, Alley E., Lauria, Alexis L., Paterson, Jeanette E., Kersey, Alexander J., Leung, Lai Yee, Burmeister, David M., Baer, David G., White, Paul W., Rasmussen, Todd E., White, Joseph M., Ronaldi, Alley E., Lauria, Alexis L., Paterson, Jeanette E., Kersey, Alexander J., Leung, Lai Yee, Burmeister, David Mark , Baer, David G., White, Paul W., Rasmussen, Todd E., White, Joseph M.

Mayo Clinic

Shock | March 2, 2022 | Volume: 57 | Issue: 5 | Pages: 732-739

10.1097/shk.0000000000001922 | PMID 35234207 Get It

ABSTRACT Introduction: Targeted regional optimization (TRO) describes partial resuscitative endovascular balloon occlusion of the aorta strategy that allows for controlled distal perfusion to balance hemostasis and tissue perfusion. This study characterized hemodynamics at specific targeted distal flow rates in a swine model of uncontrolled hemorrhage to determine if precise TRO by volume was possible. Methods: Anesthetized swine were subjected to liver laceration and randomized into TRO at distal flows of 300 mL/min (n = 8), 500 mL/min (n = 8), or 700 mL/min (n = 8). After 90 min, the animals received damage control packing and were monitored for 6 h. Hemodynamic parameters were measured continuously, and hematology and serologic labs obtained at predetermined intervals. Results: During TRO, the average percent deviation from the targeted flow was lower than 15.9% for all cohorts. Average renal flow rates were significantly different across all cohorts during TRO phase (P < 0.0001; TRO300 = 63.1 ± 1.2; TRO500 = 133.70 ± 1.93; TRO700 = 109.3 ± 2.0), with the TRO700 cohort having less renal flow than TRO500. The TRO500 and TRO700 average renal flow rates inverted during the intensive care unit phase (P < 0.0001; TRO300 = 86.20 ± 0.40; TRO500 = 148.50 ± 1.45; TRO700 = 181.1 ± 0.70). There was higher blood urea nitrogen, creatinine, and potassium in the TRO300 cohort at the end of the experiment, but no difference in lactate or pH between cohorts. Conclusion: This study demonstrated technical feasibility of TRO as a strategy to improve outcomes after prolonged periods of aortic occlusion and resuscitation in the setting of ongoing solid organ hemorrhage. A dose-dependent ischemic end-organ injury occurs beginning with partial aortic occlusion that progresses through the critical care phase, with exaggerated effect on renal function.